Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Moderate to Severe Bronchial Asthma
NCT00232050Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2002
- Primary completion
- May 2005
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Omalizumab with Placebo (2 arms). Primary endpoint: Morning Peak Expiratory Flow at 16 weeks. Started Oct 2002; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00232050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232050.